No Data
Oppenheimer Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $380
Oppenheimer Remains a Buy on Amgen (AMGN)
BofA Restarts Coverage of 11 Large-cap Biopharmas
Amgen Boosts Quarterly Dividend by Nearly 6%
Amgen Raises Qtr Dividend to $2.38 Vs. $2.25 >AMGN
Express News | Amgen Announces 2025 First Quarter Dividend